Benefits Of Using Various Starting Doses Of Atorvastatin On Achievement Of Cholesterol Targets (ACTFAST 2)

Viatris

Status and phase

Completed

Phase 4

Conditions

Cerebrovascular Accident

Peripheral Vascular Disease

Coronary Arteriosclerosis

Dyslipidemia

Diabetes Mellitus, Type 2

Treatments

Drug: Atorvastatin (Lipitor)

Study type

Interventional

Funder types

Industry

Identifiers

NCT00442325

A2581095

Details and patient eligibility

About

European physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

High cholesterol blood levels (LDL-cholesterol above 100 mg/dL up to 220 mg/dL.
Triglycerides up to 600 mg/dL.
History of coronary artery disease (ex.: heart attack, angina), stroke, diabetes or at high risk of such events.

Exclusion criteria

Pregnancy or lactation, use of high statin doses (>40mg) at baseline, liver or renal problems
Use of other drugs that would interfere with evaluation of efficacy or cause safety problems
Uncontrolled hypertension, diabetes or hypothyroidism
Recent cardiac event of procedure
High baseline CPK levels